Lilly's Ebglyss meets primary and secondary endpoints in Phase 3b ADtouch study

Eli Lilly said its Ebglyss (lebrikizumab) monotherapy met primary and secondary endpoints at week 16 in the Phase 3b ADtouch study, showing significant and rapid improvements in hand and foot skin clearance, itch and pain in adults and adolescents with moderate-to-severe hand and foot atopic dermatitis.

Detected & updated continuously · Source: Nebula